BASKING RIDGE, N.J. , June 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR) today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full their option to purchase an additional 780,000 shares of common
ITP program providing reimbursement for gammaCore ™ extended to March. 31, 2021 with option for additional three years The potential contract value if the three-year extension option is exercised could be up to approximately £3.6 million (or approximately $4.6 million based on the current exchange
ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020 BASKING RIDGE, N.J. , April 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service ( NHS ) has exercised its option to
ROCKAWAY, N.J. , April 04, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase by clinicians
ROCKAWAY, N.J. , May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National
ROCKAWAY, N.J. , Jan. 27, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire (nVNS) has been included in a new long-term reimbursement policy launched by Matthew Whitty , Director of Innovation
ROCKAWAY, NJ , April 26, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Johns Hopkins University School of Medicine is starting an investigator-initiated trial of non-invasive vagus nerve stimulation (nVNS)
BASKING RIDGE, N.J. , June 21, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) today announced the pricing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $15.00 per share. All of the shares of common stock are being offered by
ROCKAWAY, N.J. , April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a license to import, distribute and market gammaCore Sapphire™, non-invasive vagus nerve stimulator
Reimbursement for gammaCore™ in England BASKING RIDGE, N.J. , Aug. 24, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Official Journal of the European Union (OJEU) has published a Voluntary ex-ante Transparency